CATX · AMEX
Perspective Therapeutics, Inc.
$0.92 +0.05 (+5.17%)
Company overview
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic and abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
- Sector
- Healthcare
- Industry
- Medical - Devices
- Exchange
- AMEX
- Market cap
- $105M
- Employees
- 138
- Headquarters
- Seattle, WA
- Website
- perspectivetherapeutics.com
- CEO
- Johan Spoor
- Listed
- November 10, 2005
- P/E
- -0.65
- Dividend yield
- 0.00%
Company financials
- Revenue
- $575,000
- Gross profit
- -$2.1M
- Operating income
- -$120M
- EBITDA
- -$111M
- Net income
- -$111M
- EPS
- -$1.41
- Total assets
- $411M
- Total debt
- $2.6M
- Gross margin
- -358.09%
- Net margin
- -19,327.48%
- Earnings yield
- -153.26%
CATX
1D
AMEX
O0.90H0.96L0.84C0.87-0.01 (-0.59%)Vol6.77M
News